These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 35675756)
1. trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease. Wang JZ; Shimadate Y; Kise M; Kato A; Jia YM; Li YX; Fleet GWJ; Yu CY Eur J Med Chem; 2022 Aug; 238():114499. PubMed ID: 35675756 [TBL] [Abstract][Full Text] [Related]
2. Nanomolar β-glucosidase and β-galactosidase inhibition by enantiomeric α-1-C-alkyl-1,4-dideoxy-1,4-imino-arabinitol derivatives. Zi D; Song YY; Lu TT; Kise M; Kato A; Wang JZ; Jia YM; Li YX; Fleet GWJ; Yu CY Eur J Med Chem; 2023 Feb; 247():115056. PubMed ID: 36603505 [TBL] [Abstract][Full Text] [Related]
3. Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for Gaucher disease. Kato A; Nakagome I; Sato K; Yamamoto A; Adachi I; Nash RJ; Fleet GW; Natori Y; Watanabe Y; Imahori T; Yoshimura Y; Takahata H; Hirono S Org Biomol Chem; 2016 Jan; 14(3):1039-48. PubMed ID: 26633162 [TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of 6-C-alkyl-DMDP type nanomolar inhibitors of β-galactosidase and β-glucosidase based on broussonetine S and related derivatives. Gao FT; Wu QK; Zhang M; Shimadate Y; Qian G; Song YY; Kato A; Li YX; Jia YM; Fleet GWJ; Yu CY Eur J Med Chem; 2024 Sep; 275():116570. PubMed ID: 38878517 [TBL] [Abstract][Full Text] [Related]
5. Human Acid β-Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease. Parmeggiani C; Catarzi S; Matassini C; D'Adamio G; Morrone A; Goti A; Paoli P; Cardona F Chembiochem; 2015 Sep; 16(14):2054-64. PubMed ID: 26376302 [TBL] [Abstract][Full Text] [Related]
6. Rapid modifications of N-substitution in iminosugars: development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease. Cheng WC; Weng CY; Yun WY; Chang SY; Lin YC; Tsai FJ; Huang FY; Chen YR Bioorg Med Chem; 2013 Sep; 21(17):5021-8. PubMed ID: 23880081 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and glycosidase inhibition of C-4 branched LAB and DAB derivatives. Wang JZ; Cheng B; Kato A; Kise M; Shimadate Y; Jia YM; Li YX; Fleet GWJ; Yu CY Eur J Med Chem; 2022 Apr; 233():114230. PubMed ID: 35255314 [TBL] [Abstract][Full Text] [Related]
8. Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts. Mena-Barragán T; García-Moreno MI; Nanba E; Higaki K; Concia AL; Clapés P; García Fernández JM; Ortiz Mellet C Eur J Med Chem; 2016 Oct; 121():880-891. PubMed ID: 26361824 [TBL] [Abstract][Full Text] [Related]
9. Design of a New α-1- Nakagome I; Kato A; Yamaotsu N; Yoshida T; Ozawa SI; Adachi I; Hirono S Molecules; 2018 Oct; 23(10):. PubMed ID: 30340368 [TBL] [Abstract][Full Text] [Related]
10. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Lieberman RL; Wustman BA; Huertas P; Powe AC; Pine CW; Khanna R; Schlossmacher MG; Ringe D; Petsko GA Nat Chem Biol; 2007 Feb; 3(2):101-7. PubMed ID: 17187079 [TBL] [Abstract][Full Text] [Related]
11. Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease. Schönemann W; Gallienne E; Ikeda-Obatake K; Asano N; Nakagawa S; Kato A; Adachi I; Górecki M; Frelek J; Martin OR ChemMedChem; 2013 Nov; 8(11):1805-17. PubMed ID: 24115322 [TBL] [Abstract][Full Text] [Related]
12. Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease. Orwig SD; Tan YL; Grimster NP; Yu Z; Powers ET; Kelly JW; Lieberman RL Biochemistry; 2011 Dec; 50(49):10647-57. PubMed ID: 22047104 [TBL] [Abstract][Full Text] [Related]
13. Polyhydroxylated bicyclic isoureas and guanidines are potent glucocerebrosidase inhibitors and nanomolar enzyme activity enhancers in Gaucher cells. Trapero A; Alfonso I; Butters TD; Llebaria A J Am Chem Soc; 2011 Apr; 133(14):5474-84. PubMed ID: 21413704 [TBL] [Abstract][Full Text] [Related]
14. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. Khanna R; Benjamin ER; Pellegrino L; Schilling A; Rigat BA; Soska R; Nafar H; Ranes BE; Feng J; Lun Y; Powe AC; Palling DJ; Wustman BA; Schiffmann R; Mahuran DJ; Lockhart DJ; Valenzano KJ FEBS J; 2010 Apr; 277(7):1618-38. PubMed ID: 20148966 [TBL] [Abstract][Full Text] [Related]
15. Multivalent pyrrolidines acting as pharmacological chaperones against Gaucher disease. Borie-Guichot M; Lan Tran M; Garcia V; Oukhrib A; Rodriguez F; Turrin CO; Levade T; Génisson Y; Ballereau S; Dehoux C Bioorg Chem; 2024 May; 146():107295. PubMed ID: 38513326 [TBL] [Abstract][Full Text] [Related]
16. Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease. Trapero A; González-Bulnes P; Butters TD; Llebaria A J Med Chem; 2012 May; 55(9):4479-88. PubMed ID: 22512696 [TBL] [Abstract][Full Text] [Related]
17. New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease. Li Z; Li T; Dai S; Xie X; Ma X; Zhao W; Zhang W; Li J; Wang PG Chembiochem; 2013 Jul; 14(10):1239-47. PubMed ID: 23775891 [TBL] [Abstract][Full Text] [Related]